Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash & Equivalents (2018 - 2025)

AdaptHealth (AHCO) has 8 years of Cash & Equivalents data on record, last reported at $106.1 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 3.29% year-over-year to $106.1 million; the TTM value through Dec 2025 reached $106.1 million, down 3.29%, while the annual FY2025 figure was $106.1 million, 3.29% down from the prior year.
  • Cash & Equivalents reached $106.1 million in Q4 2025 per AHCO's latest filing, up from $80.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $336.7 million in Q3 2021 and bottomed at $45.1 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $107.0 million, with a median of $100.8 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: soared 174.35% in 2021, then tumbled 69.08% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $149.6 million in 2021, then crashed by 69.08% to $46.3 million in 2022, then skyrocketed by 66.69% to $77.1 million in 2023, then surged by 42.28% to $109.7 million in 2024, then dropped by 3.29% to $106.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $106.1 million in Q4 2025, $80.4 million in Q3 2025, and $68.6 million in Q2 2025.